How I learned to love carrots: the role of the cytoskeleton in shaping plant cells

The carrot cell suspension was originally used because it provided a model system for studying directional cell expansion - a key process in plant morphogenesis. Early immunofluorescence studies of plant microtubules, using these cells, provided hints that the cortical array of microtubules was dynamic and this was later confirmed by microinjection studies on plant epidermal cells. A nonfixation approach for detecting F-actin was then developed on these cells and showed that, unlike animal cells, actin filaments remained associated with the nucleus throughout division and could have a role in aligning the plane of cell division. Currently, we are using detergent-extracted carrot cytoskeletons for isolating microtubule-associated proteins (MAPs). I discuss how MAPs may be involved in the oriented deposition of cellulose in the cell wall.     

Emotional regulation, or: how I learned to stop worrying and love the nucleus accumbens

How does the brain control emotion? In this issue of Neuron, Wager et al. use a novel mediation analysis of neuroimaging data to show two independent pathways for the control of emotion by the prefrontal cortex: a path through the amygdala predicts a greater negative emotional response, and a path through the nucleus accumbens/ventral striatum predicts a greater positive response.     

Biofuel technologies: Lessons learned and pathways to decarbonization

This Opinion highlights several successful cases of biofuel technologies recently described by the IEA Bioenergy Intertask Report on Lessons Learned. The report discussed the potential of biofuels to contribute to a significant market supply, thus replacing fossil fuels and mitigating global warming, and it underscores the challenges in expanding biofuel production and replicating successful models between countries and regions. Based on the lessons learned from conventional, established technologies, the authors analyzed policies, feedstocks, products, technologies, economics, environmental concerns, social aspects, scalability, and ease of implementation and replication in different countries or regions. There are blending mandates in place around the world to foster the use of biofuels. Dependence on the availability and price fluctuations of crop feedstocks may limit biofuel production in certain circumstances. Legal restrictions on using food crops as feedstocks present obstacles to scaling up production. Temporary constraints related to feedstock costs and availability, as evidenced by changes and postponements of biofuel blending mandates in various countries (particularly during the COVID-19 pandemic) also pose challenges. Technological hurdles exist for advanced biofuels that implicate premium pricing. Still, 2G ethanol from sugarcane meets very strict feedstock requirements with a carbon footprint so low that only electric vehicles charged in Norway could have life-cycle GHG emissions at the same level as a 2G ethanol-fueled combustion engine car. The authors evaluate whether and how much electrification could contribute to advance the decarbonization efforts in different countries. Drawing from these observations, the authors express their viewpoints to assist researchers and policymakers in the energy sector in formulating viable approaches to combat the climate crisis.     

Human genetic technologies,European governance and the politics of bioethics

With human genetic technologies now an important area of European research and development, bioethics is becoming increasingly important in its regulation and future. As regulatory decisions are also statements about who should get what, bioethics cannot avoid political controversy. Can bioethics sustain its claimed role as authoritative adviser to decision makers, or will its attempts to reach a consensus on human genetic technologies be perceived as the actions of an ambitious interest group? What, in short, is its political future in Europe and elsewhere?     

Identities in conflict: The Aboriginal question and the politics of recognition in Quebec

The will to have one's own particular identity universally acknowledged and respected is now one of the most significant determinants of the sociopolitical dynamic of contemporary modern societies. However, the actual recognition of difference is more often than not an unsatisfactory and disappointing experience for many of the groups and communities striving for that recognition. The recent experience of Canadian Aboriginal peoples is a case in point. This article looks at the struggle of Aboriginal nations for recognition in one particular region of Canada, the province of Quebec. Indeed, Quebec offers a revealing case‐study of the peculiarities of the politics of recognition. For over three decades now, the French‐speaking majority of Quebec has striven to assert its ethnocultural distinctiveness and laid claims to a special status within the Canadian political and constitutional framework. Today, both Quebecers and Aboriginals are recognition seekers within the Canadian polity. As a result, their relationship is inevitably marked by their respective but competing attempt to draw the attention of the Canadian state to their particular identity claims. In recent years, this has led to a highly conflictual dynamic which considerably strains any hope of social and cultural coexistence. The article examines the particularities of the politics of recognition in the Quebec context. Its objective is twofold. First, it should serve to shed some light on the manifestations of Aboriginal ethnonationalism in Canada. Secondly, it seeks to illustrate the limitations and paradoxical nature of the politics of recognition within a liberal framework.     

Three decades of nucleic acid aptamer technologies: Lessons learned,progress and opportunities on aptamer development

Aptamers are short single-stranded nucleic acid sequences capable of binding to target molecules in a way similar to antibodies. Due to various advantages such as prolonged shelf life, low batch to batch variation, low/no immunogenicity, freedom to incorporate chemical modification for enhanced stability and targeting capacity, aptamers quickly found their potential in diverse applications ranging from therapy, drug delivery, diagnosis, and functional genomics to bio-sensing. Aptamers are generated by a process called SELEX. However, the current overall success rate of SELEX is far from being satisfactory, and still presents a major obstacle for aptamer-based research and application. The need for an efficient selection strategy consisting of defined procedures to deal with a wide variety of targets is significantly important. In this work, by analyzing key aspects of SELEX including initial library design, target preparation, PCR optimization, and single strand DNA separation, we provide a comprehensive analysis of individual steps to facilitate researchers intending to develop personalized protocols to address many of the obstacles in SELEX. In addition, this review provides suggestions and opinions for future aptamer development procedures to address the concerns on key SELEX steps, and post-SELEX modifications.     

Post-race,post politics: the paradoxical rise of culture after multiculturalism

Declarations of the end of race ignore the continuing impact of racism upon socio-economic inequality in ‘racial states’. Nevertheless, the idea of post-racialism has gained ground in a post-9/11 era, defined by a growing suspicion of diversity. Clearly racialized, this suspicion is couched in cultural-civilizational terms that attempt to avoid the charge of racism. Hence, attempts to counteract the purported failure of multiculturalism in Europe today pose culturalist solutions to problems deemed to originate from an excess of cultural diversity. This is part of a deepening culturalization of politics in which the post-race argument belongs to a post-political logic that shuns political explanations of unrest and widening disintegration in favour of reductive culturalist ones. The culturalization of politics is elaborated by relating it to the displacement of the political that originated with the nineteenth-century ascendance of race, thus setting ‘post-racialism’ firmly within the history of modern racism.     

Thematic review series: lipid posttranslational modifications. GPI anchoring of protein in yeast and mammalian cells, or: how we learned to stop worrying and love glycophospholipids

Glycosylphosphatidylinositol (GPI) anchoring of cell surface proteins is the most complex and metabolically expensive of the lipid posttranslational modifications described to date. The GPI anchor is synthesized via a membrane-bound multistep pathway in the endoplasmic reticulum (ER) requiring >20 gene products. The pathway is initiated on the cytoplasmic side of the ER and completed in the ER lumen, necessitating flipping of a glycolipid intermediate across the membrane. The completed GPI anchor is attached to proteins that have been translocated across the ER membrane and that display a GPI signal anchor sequence at the C terminus. GPI proteins transit the secretory pathway to the cell surface; in yeast, many become covalently attached to the cell wall. Genes encoding proteins involved in all but one of the predicted steps in the assembly of the GPI precursor glycolipid and its transfer to protein in mammals and yeast have now been identified. Most of these genes encode polytopic membrane proteins, some of which are organized in complexes. The steps in GPI assembly, and the enzymes that carry them out, are highly conserved. GPI biosynthesis is essential for viability in yeast and for embryonic development in mammals. In this review, we describe the biosynthesis of mammalian and yeast GPIs, their transfer to protein, and their subsequent processing.     

Sex,gender, and pharmaceutical politics: From drug development to marketing

Background: Biological sex differences and sociocultural gender norms affect the provision of health care products and services, but there has been little explicit analysis of the impact of sex differences and gender norms on the regulation of pharmaceutical development and marketing.Objectives: This article provides an overview of the regulation of pharmaceuticals and examines the ways that regulatory agencies account for sex and gender in their review of scientific data and marketing materials.Methods: The primary focus is on the US context, but information is also included about regulatory models in Europe, Canada, and Japan for comparative purposes. Specific examples show how sex differences and gender norms influence scientific and policy decisions about pharmaceuticals.Results: The United States and Canada were found to be the only countries that have explicit requirements to include women in clinical trials and to perform sex-based subgroup analysis on study results. The potential influence of politics on regulatory decisions may have led to an uneven application of standards, as seen through the examples of mifepristone (for abortion) and sildenafil citrate (for erectile dysfunction). Three detailed case studies illustrate the importance of considering sex and gender in pharmaceutical development and marketing: Phase I clinical trials; human papillomavirus quadrivalent vaccine; and tegaserod, a drug for irritable bowel syndrome.Conclusions: Sex and gender play important roles in pharmaceutical regulation, from the design of clinical trials and the approval of new drugs to advertising and postmarketing surveillance. However, regulatory agencies pay insufficient attention to both biological sex differences and sociocultural gender norms. This disregard perpetuates inequalities by ignoring drug safety problems that predominate in women and by allowing misleading drug marketing that reinforces gender stereotypes. Recommendations have been made to improve the regulation of pharmaceuticals in regard to sex and gender.     

Studies of the mortality of atomic bomb survivors. report 12, part I. Cancer: 1950-1990

This continues the series of periodic general reports on cancer mortality in the cohort of A-bomb survivors followed by the Radiation Effects Research Foundation. The follow-up is extended by the 5 years 1986-1990, and analysis includes an additional 10,500 survivors with recently estimated radiation doses. Together these extensions add about 550,000 person-years of follow-up. The cohort analyzed consists of 86,572 subjects, of which about 60% have dose estimates of at least 0.005 Sv. During 1950-1990 there have been 3086 and 4741 cancer deaths for the less than and greater than 0.005 Sv groups, respectively. It is estimated that among these there have been approximately 420 excess cancer deaths during 1950-1990, of which about 85 were due to leukemia. For cancers other than leukemia (solid cancers), about 25% of the excess deaths in 1950-1990 occurred during the last 5 years; for those exposed as children this figure is nearly 50%. For leukemia only about 3% of the excess deaths in 1950-1990 occurred in the last 5 years. Whereas most of the excess for leukemia occurred in the first 15 years after exposure, for solid cancers the pattern of excess risk is apparently more like a life-long elevation of the natural age-specific cancer risk. Taking advantage of the lengthening follow-up, increased attention is given to clarifying temporal patterns of the excess cancer risk. Emphasis is placed on describing these patterns in terms of absolute excess risk, as well as relative risk. For example: (a) although it is becoming clearer that the excess relative risk for those exposed as children has declined over the follow-up, the excess absolute risk has increased rapidly with time; and (b) although the excess relative risk at a given age depends substantially on sex and age at exposure, the age-specific excess absolute risk depends little on these factors. The primary estimates of excess risk are now given as specific to sex and age at exposure, and these include projections of dose-specific lifetime risks for this cohort. The excess lifetime risk per sievert for solid cancers for those exposed at age 30 is estimated at 0.10 and 0.14 for males and females, respectively. Those exposed at age 50 have about one-third these risks. Projection of lifetime risks for those exposed at age 10 is more uncertain. Under a reasonable set of assumptions, estimates for this group range from about 1.0-1.8 times the estimates for those exposed at age 30. The excess life-time risk for leukemia at 1 Sv for those exposed at either 10 or 30 years is estimated as about 0.015 and 0.008 for males and females, respectively. Those exposed at age 50 have about two-thirds that risk. Excess risks for solid cancer appear quite linear up to about 3 Sv, but for leukemia apparent nonlinearity in dose results in risks at 0.1 Sv estimated at about 1/20 of those for 1.0 Sv. Site-specific risk estimates are given, but it is urged that great care be taken in interpreting these, because most of their variation can be explained simply by imprecision in the estimates.     

To the future: An ecology of love,hope, and action

This is an edited version of a keynote address given at the 2023 Ecological Society of Australia conference ( https://youtu.be/0JDJ9RdIkP4 ). I argue that the practice of ecology gifts us a unique capability to see and understand the beauty, intricacy and wonder of the natural world, but also powerful insight into biodiversity loss and its consequences. With such privilege we should take more responsibility for its protection. We should recognize that love drives our concern for nature and that emotion renders us more persuasive advocates. Despair at environmental loss is understandable but unhelpful, and we must find hope and build from it. Such hope comes, for example, from a sense of community connection to and concern for nature; in increasingly bold commitments by governments and many organizations to protect biodiversity; in the increased recognition and respect shown in Australia for First Nations management and perspectives on responsibility for country; and in those (albeit still too few) success stories of recovery.